Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophageal Cancer Expressing PD-L1 (CPS ≥10)

 Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophageal Cancer Expressing PD-L1 (CPS ≥10)

Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophageal Cancer Expressing PD-L1 (CPS ≥10)

Shots:

  • The approval is based on two studies, KEYNOTE-181 study results involve assessing of Keytruda (200mg, q3w) vs CT (paclitaxel/docetaxel) in 628 patients in a ratio (1:1) with 1L+ LA/m- EC with disease progression. The KEYNOTE-180 study results involve assessing of Keytruda in 121 patients with 1L+ LA/m- EC with disease progression
  • KEYNOTE-181 results: In ESCC patients with PD-L1 expression (CPS ≥10) (80% vs 88%); OS (10.3 vs 6.7mos.); mPFS (3.2 vs 2.3 mos.); ORR (22% vs 7%); CRR (5% vs 1%); DOR (9.3 vs 7.7mos.). KEYNOTE-180 results: 20% ORR with DOR ranged from 4.2-25.1+ mos.
  • Keytruda is a mAb targeting PD-1 and blocking its interaction with PD-L1 and PD-L2 thereby activating T-lymphocytes affecting both tumor and healthy cells

 Click here to­ read full press release/ article | Ref: Merck | Image: Austin Chronicle

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post